Advertisement
Canada markets open in 6 hours 36 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7310
    +0.0012 (+0.17%)
     

  • CRUDE OIL

    82.87
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    87,904.41
    -3,466.66 (-3.79%)
     

  • CMC Crypto 200

    1,391.48
    +8.90 (+0.64%)
     

  • GOLD FUTURES

    2,332.10
    -6.30 (-0.27%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,428.00
    -236.50 (-1.34%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6814
    -0.0005 (-0.07%)
     

Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Onconova Therapeutics, Inc.
·2 min read

NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 29, 2021 through December 2, 2021.

A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginning today at 10:00 a.m. ET. The presentation can be viewed via the Piper Sandler presentation library on the conference site through December 2, 2021 for all registered attendees, and on the “Corporate Events and Presentations” section of the Onconova website.

The Company will also be participating in 1x1 meetings November 30, 2021 through December 2, 2021. Meetings can be requested exclusively via Piper Sandler.

About Onconova Therapeutics

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

ADVERTISEMENT

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors
929-469-3859
bmackle@lifesciadvisors.com